AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9210689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice daily for 10 days)
Number of subjects: 690
Study 9210689 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily for 10 days)
Number of subjects: 690
Study 9210689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 690
Study 9210689 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 690
Study 7968751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out intervention
Number of subjects: 342
Study 7968751 — intervention group
Group type: COMPARATOR
Intervention: Advice from GP
Number of subjects: 342
Study 7968751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 342
Study 3614956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.11 mg/kg diazepam
Number of subjects: 20
Study 3614956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.66 microgram/kg fentanyl
Number of subjects: 20
Study 3614956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diazepam and fentanyl doses
Number of subjects: 20
Study 3614956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29268206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) 10000lx
Number of subjects: 32
Study 29268206 — intervention group
Group type: COMPARATOR
Intervention: Dim light (DL, < 500lx)
Number of subjects: 32
Study 27282265 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group)
Number of subjects: 501
Study 27282265 — intervention group
Group type: COMPARATOR
Intervention: 40 mg esomeprazole daily (monotherapy group)
Number of subjects: 501
Study 24955584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 63
Study 24955584 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 63
Study 23301435 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored educational intervention designed to build family capacity
Number of subjects: 29
Study 23301435 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 29
Study 20093623 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW) 100 mL daily for 3 weeks
Number of subjects: 80
Study 20093623 — intervention group
Group type: COMPARATOR
Intervention: Water (100 mL) daily for 3 weeks
Number of subjects: 80
Study 20093623 — intervention group
Group type: COMPARATOR
Intervention: Beer (250 mL) daily for 3 weeks
Number of subjects: 80
Study 20093623 — intervention group
Group type: COMPARATOR
Intervention: Vodka (30 mL) daily for 3 weeks
Number of subjects: 80
Study 18565159 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 16195036 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 44
Study 16195036 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 44
Study 16195036 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and ibuprofen (combination)
Number of subjects: 44
Study 16195036 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 12555175 — intervention group
Group type: EXPERIMENTAL
Intervention: Plugged group (n = 128)
Number of subjects: 262
Study 12555175 — intervention group
Group type: COMPARATOR
Intervention: Unplugged group (n = 134)
Number of subjects: 262
Study 11200349 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 141
Study 11200349 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA followed by Palmaz stents
Number of subjects: 141
Study 9863122 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine of replenishing Qi and nourishing Yin (RQNY) combined with a small dosage of Tapazol
Number of subjects: 42
Study 9863122 — intervention group
Group type: COMPARATOR
Intervention: Tapazol alone
Number of subjects: 42
Study 9863122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (TCM + Tapazol)
Number of subjects: 42
Study 9863122 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Tapazol)
Number of subjects: 42
Study 8512760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% w/v cyclopentolate hydrochloride
Number of subjects: 8
Study 8512760 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate in saline
Number of subjects: 8
Study 8512760 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate in acetate buffer
Number of subjects: 8
Study 8512760 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclopentolate polygalacturonate
Number of subjects: 8
Study 3815397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) 10 mg
Number of subjects: 0
Study 3815397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) 5 mg
Number of subjects: 0
Study 3815397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) 10 mg
Number of subjects: 0
Study 3815397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 5 mg
Number of subjects: 0
Study 31099033 — intervention group
Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP in low-risk group
Number of subjects: 105
Study 31099033 — intervention group
Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP in intermediate-risk group
Number of subjects: 105
Study 31099033 — intervention group
Group type: COMPARATOR
Intervention: CHOP-14 in intermediate-risk group
Number of subjects: 105
Study 28860165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient ingestion (essential amino acids and maltodextrin)
Number of subjects: 12
Study 25754458 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling (MUS)
Number of subjects: 134
Study 25754458 — intervention group
Group type: COMPARATOR
Intervention: Control group (prolapse repair only)
Number of subjects: 134
Study 23764005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily for 6 months
Number of subjects: 900
Study 23764005 — intervention group
Group type: COMPARATOR
Intervention: Initial tinzaparin 175 IU/kg once daily for 5-10 days and dose-adjusted warfarin (target INR 2.0-3.0) for 6 months
Number of subjects: 900
Study 20978642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CF)
Number of subjects: 20
Study 20978642 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F (OB)
Number of subjects: 20
Study 20978642 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound diamond bur (UB)
Number of subjects: 20
Study 20978642 — intervention group
Group type: COMPARATOR
Intervention: Conventional diamond bur (CB)
Number of subjects: 20
Study 19265308 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand acupuncture therapy (including hand acupuncture and press-pellets based on corresponding points)
Number of subjects: 40
Study 19265308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 16325440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of racemic albuterol from dry powder inhalers
Number of subjects: 0
Study 14696127 — intervention group
Group type: COMPARATOR
Intervention: Leisure-time physical activity (light)
Number of subjects: 29133
Study 14696127 — intervention group
Group type: COMPARATOR
Intervention: Leisure-time physical activity (moderate)
Number of subjects: 29133
Study 14696127 — intervention group
Group type: COMPARATOR
Intervention: Leisure-time physical activity (heavy)
Number of subjects: 29133
Study 14696127 — intervention group
Group type: COMPARATOR
Intervention: Occupational physical activity
Number of subjects: 29133
Study 11726410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 4 mg
Number of subjects: 0
Study 11726410 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 6 mg
Number of subjects: 0
Study 9743164 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxair Autohaler (1,200 microg pirbuterol) plus saline solution by nebulizer
Number of subjects: 24
Study 9743164 — intervention group
Group type: COMPARATOR
Intervention: Placebo by Autohaler plus 2,500 microg albuterol via nebulizer
Number of subjects: 24
Study 7522415 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen ablation therapy (3 months of goserelin acetate and flutamide)
Number of subjects: 27
Study 7522415 — intervention group
Group type: COMPARATOR
Intervention: Hormonally untreated, grade-matched prostatic adenocarcinomas (control)
Number of subjects: 27
Study 3381269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopsorine A (CsA)
Number of subjects: 40
Study 3381269 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (corticosteroids/Leukeran)
Number of subjects: 40
Study 31143777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Niacinamide
Number of subjects: 30
Study 31143777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Retinoic Acid
Number of subjects: 30
Study 31143777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28684357 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐Helping‐Hand (AHH) intervention with 6 weekly psychoeducational sessions and boosters
Number of subjects: 348
Study 28684357 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 348
Study 24997645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine
Number of subjects: 3046
Study 24997645 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine
Number of subjects: 3046
Study 24997645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (pT2-4 cancer)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine (pT2-4 cancer)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (total thyroidectomy)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine (total thyroidectomy)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radioiodine (thyrotropin α stimulation)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: COMPARATOR
Intervention: High-dose radioiodine (thyrotropin α stimulation)
Number of subjects: 3046
Study 24997645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose radioiodine
Number of subjects: 3046
Study 24099279 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0941 (fasted)
Number of subjects: 0
Study 24099279 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0941 (high-fat meal)
Number of subjects: 0
Study 24099279 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole + GDC-0941 (fasted)
Number of subjects: 0
Study 24099279 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole + GDC-0941 (high-fat meal)
Number of subjects: 0
Study 20848317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy followed by rapid maxillary expansion (RME)
Number of subjects: 31
Study 20848317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) followed by adeno-tonsillectomy
Number of subjects: 31
Study 19366274 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan once daily (day 1: 5 mg; days 2-6: 2.5 mg)
Number of subjects: 26
Study 19366274 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan twice daily (day 1: 5 mg [10 mg total]; days 2-6: 2.5 mg [5 mg total])
Number of subjects: 26
Study 19366274 — intervention group
Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 26
Study 19366274 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC users
Number of subjects: 26
Study 19366274 — intervention group
Group type: COMPARATOR
Intervention: Non-ECC users
Number of subjects: 26
Study 16709697 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 23
Study 16709697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15290418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) + noradrenaline (5 micro g)
Number of subjects: 30
Study 15290418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 30
Study 15290418 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (Control)
Number of subjects: 30
Study 11250190 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm intermittent antegrade blood cardioplegia (37 degrees C)
Number of subjects: 30
Study 11250190 — intervention group
Group type: COMPARATOR
Intervention: Cold intermittent antegrade blood cardioplegia (4 degrees C)
Number of subjects: 30
Study 8988994 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 49
Study 8988994 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (HHD)
Number of subjects: 49
Study 8548967 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d. for 6 weeks
Number of subjects: 40
Study 8548967 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 100 micrograms q.i.d. for 6 weeks
Number of subjects: 40
Study 8548967 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 40
Study 8548967 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 40
Study 2364464 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Yanggan Gao (OG)
Number of subjects: 96
Study 2364464 — intervention group
Group type: COMPARATOR
Intervention: Three charred medicinal herbs (CG)
Number of subjects: 96
Study 385457 — intervention group
Group type: EXPERIMENTAL
Intervention: pepstatin
Number of subjects: 0
Study 385457 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal mask (ONM)
Number of subjects: 29
Study 31884409 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask (NM)
Number of subjects: 29
Study 31884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask combined with oral shield device (NMS)
Number of subjects: 29
Study 30689671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution strategies for trachoma elimination
Number of subjects: 988
Study 28421656 — intervention group
Group type: EXPERIMENTAL
Intervention: Boesenbergia pandurata ethanol extract (BPE) containing 8% of panduratin A
Number of subjects: 92
Study 28421656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 25817067 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable shocks (unpredictability group)
Number of subjects: 0
Study 25817067 — intervention group
Group type: COMPARATOR
Intervention: Blocked shocks (predictability group)
Number of subjects: 0
Study 24102972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes (reduction in energy, fat, and sodium intake; increase in fruit, vegetable, and fibre intake)
Number of subjects: 736
Study 24102972 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fruit intake
Number of subjects: 736
Study 24102972 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vegetable intake
Number of subjects: 736
Study 24102972 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductions in fat, energy, and sodium intake
Number of subjects: 736
Study 24102972 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin C increase
Number of subjects: 736
Study 22331175 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (4 mg)
Number of subjects: 21
Study 22331175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20192884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective quality control system
Number of subjects: 0
Study 20192884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17616259 — intervention group
Group type: EXPERIMENTAL
Intervention: THEME (Update day plus 12 weekly worksheets, feedback to audiotaped sessions, and three 30 minute sessions of telephone coaching)
Number of subjects: 54
Study 17616259 — intervention group
Group type: COMPARATOR
Intervention: Control (Update day in MI)
Number of subjects: 54
Study 16157230 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions for heroin and cocaine dependence
Number of subjects: 286
Study 12377405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 21 mg transdermal patch
Number of subjects: 30
Study 12377405 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 30
Study 10203379 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)‐2 therapy
Number of subjects: 0
Study 10203379 — intervention group
Group type: COMPARATOR
Intervention: Control group (HAART only)
Number of subjects: 0
Study 8880837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory mediators (IM) injected in acidic solution (BK, 5-HT, HIS, PGE2) at concentrations of 10(-7) M, 10(-6) M, and 10(-5) M.
Number of subjects: 6
Study 8880837 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain phosphate buffer (pH 5.2) injected into acidotic skin after IM application.
Number of subjects: 6
Study 8880837 — intervention group
Group type: COMPARATOR
Intervention: Negative control: IM in neutral solution injected into normal skin continuously infiltrated with buffer solution at pH 7.4.
Number of subjects: 6
Study 1947601 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (96 meq/day)
Number of subjects: 0
Study 1947601 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 6341388 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital cobalt irradiation combined with systemic 6 alpha‐methylprednisolone (methylprednisolone)
Number of subjects: 48
Study 6341388 — intervention group
Group type: COMPARATOR
Intervention: Systemic methylprednisolone alone
Number of subjects: 48
Study 30808321 — intervention group
Group type: EXPERIMENTAL
Intervention: LTOT 24 h/day
Number of subjects: 2126
Study 30808321 — intervention group
Group type: COMPARATOR
Intervention: LTOT 15 h/day
Number of subjects: 2126
Study 27146061 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-session co-parent training groups (n=140 couples)
Number of subjects: 209
Study 27146061 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control groups with referral to local services as necessary (n=69 couples)
Number of subjects: 209
Study 26333474 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005
Study 26333474 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1005
Study 23429588 — intervention group
Group type: EXPERIMENTAL
Intervention: treprostinil diolamine alone
Number of subjects: 18
Study 23429588 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil alone
Number of subjects: 18
Study 23429588 — intervention group
Group type: EXPERIMENTAL
Intervention: combination treprostinil diolamine and sildenafil
Number of subjects: 18
Study 21153444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decomposable idioms
Number of subjects: 0
Study 21153444 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicative metaphors
Number of subjects: 0
Study 21153444 — intervention group
Group type: COMPARATOR
Intervention: Control expressions
Number of subjects: 0
Study 21153444 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity priming for idiomatic expressions
Number of subjects: 0
Study 21153444 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity priming for metaphor expressions
Number of subjects: 0
Study 19216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed teams
Number of subjects: 100
Study 19216796 — intervention group
Group type: COMPARATOR
Intervention: Ad-hoc teams
Number of subjects: 100
Study 17320023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates
Number of subjects: 0
Study 17320023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate
Number of subjects: 0
Study 17320023 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone
Number of subjects: 0
Study 17320023 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 0
Study 14992978 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 24
Study 14992978 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 14992978 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS
Number of subjects: 24
Study 11713443 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days
Number of subjects: 73
Study 11713443 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and clarithromycin (AC) for 7 days
Number of subjects: 73
Study 1401761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptoreline 0.1 mg subcutaneously three times in one day at 8 hour intervals
Number of subjects: 67
Study 1401761 — intervention group
Group type: COMPARATOR
Intervention: HCG 10,000 IU IM
Number of subjects: 67
Study 2416164 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic platelet activating factor (PAF-acether) intradermal injections of 10-100 ng
Number of subjects: 0
Study 2416164 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of H1 antihistamine mepyramin
Number of subjects: 0
Study 2416164 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-depleted skin
Number of subjects: 0
Study 30109750 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led care during labour
Number of subjects: 666
Study 30109750 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 666
Study 25775073 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured NTS training (n = 11)
Number of subjects: 23
Study 25775073 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (n = 11)
Number of subjects: 23
Study 25014007 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP LDL apheresis
Number of subjects: 19
Study 25014007 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 22688548 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI-LC diet
Number of subjects: 26
Study 22688548 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI-HC diet
Number of subjects: 26